BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8061515)

  • 1. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in the adult male rat following single injections and continuous infusion.
    Iversen PL; Mata J; Tracewell WG; Zon G
    Antisense Res Dev; 1994; 4(1):43-52. PubMed ID: 8061515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice.
    Raynaud FI; Orr RM; Goddard PM; Lacey HA; Lancashire H; Judson IR; Beck T; Bryan B; Cotter FE
    J Pharmacol Exp Ther; 1997 Apr; 281(1):420-7. PubMed ID: 9103525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo metabolic profile of a phosphorothioate oligodeoxyribonucleotide.
    Temsamani J; Roskey A; Chaix C; Agrawal S
    Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):159-65. PubMed ID: 9212906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats.
    Zhang R; Lu Z; Zhao H; Zhang X; Diasio RB; Habus I; Jiang Z; Iyer RP; Yu D; Agrawal S
    Biochem Pharmacol; 1995 Aug; 50(4):545-56. PubMed ID: 7646561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression.
    Geary RS; Leeds JM; Fitchett J; Burckin T; Truong L; Spainhour C; Creek M; Levin AA
    Drug Metab Dispos; 1997 Nov; 25(11):1272-81. PubMed ID: 9351904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats.
    Zhang R; Lu Z; Zhang X; Zhao H; Diasio RB; Liu T; Jiang Z; Agrawal S
    Clin Chem; 1995 Jun; 41(6 Pt 1):836-43. PubMed ID: 7768001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1.
    Zhang R; Diasio RB; Lu Z; Liu T; Jiang Z; Galbraith WM; Agrawal S
    Biochem Pharmacol; 1995 Mar; 49(7):929-39. PubMed ID: 7741765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells.
    Lisziewicz J; Sun D; Weichold FF; Thierry AR; Lusso P; Tang J; Gallo RC; Agrawal S
    Proc Natl Acad Sci U S A; 1994 Aug; 91(17):7942-6. PubMed ID: 8058738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes.
    Nicklin PL; Bayley D; Giddings J; Craig SJ; Cummins LL; Hastewell JG; Phillips JA
    Pharm Res; 1998 Apr; 15(4):583-91. PubMed ID: 9587955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration.
    Phillips JA; Craig SJ; Bayley D; Christian RA; Geary R; Nicklin PL
    Biochem Pharmacol; 1997 Sep; 54(6):657-68. PubMed ID: 9310342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of antisense oligonucleotides.
    Agrawal S; Temsamani J; Galbraith W; Tang J
    Clin Pharmacokinet; 1995 Jan; 28(1):7-16. PubMed ID: 7712663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
    Saijo Y; Perlaky L; Wang H; Busch H
    Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects.
    Zhang R; Yan J; Shahinian HK; Amin G; Lu Z; Liu T; Saag MS; Jiang Z; Temsamani J; Martin RR
    Clin Pharmacol Ther; 1995 Jul; 58(1):44-53. PubMed ID: 7628182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and metabolism of an oligodeoxynucleotide phosphorothioate (GEM91) in cynomolgus monkeys following intravenous infusion.
    Grindel JM; Musick TJ; Jiang Z; Roskey A; Agrawal S
    Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):43-52. PubMed ID: 9512095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey.
    Yu RZ; Geary RS; Leeds JM; Watanabe T; Moore M; Fitchett J; Matson J; Burckin T; Templin MV; Levin AA
    J Pharm Sci; 2001 Feb; 90(2):182-93. PubMed ID: 11169535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.
    Levin AA
    Biochim Biophys Acta; 1999 Dec; 1489(1):69-84. PubMed ID: 10806998
    [No Abstract]   [Full Text] [Related]  

  • 17. Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion.
    Broaddus WC; Prabhu SS; Gillies GT; Neal J; Conrad WS; Chen ZJ; Fillmore H; Young HF
    J Neurosurg; 1998 Apr; 88(4):734-42. PubMed ID: 9525721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracerebral and intrathecal infusion of the TGF-beta 2-specific antisense phosphorothioate oligonucleotide AP 12009 in rabbits and primates: toxicology and safety.
    Schlingensiepen R; Goldbrunner M; Szyrach MN; Stauder G; Jachimczak P; Bogdahn U; Schulmeyer F; Hau P; Schlingensiepen KH
    Oligonucleotides; 2005; 15(2):94-104. PubMed ID: 15989424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man.
    Iversen PL; Copple BL; Tewary HK
    Toxicol Lett; 1995 Dec; 82-83():425-30. PubMed ID: 8597088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic properties of several novel oligonucleotide analogs in mice.
    Crooke ST; Graham MJ; Zuckerman JE; Brooks D; Conklin BS; Cummins LL; Greig MJ; Guinosso CJ; Kornbrust D; Manoharan M; Sasmor HM; Schleich T; Tivel KL; Griffey RH
    J Pharmacol Exp Ther; 1996 May; 277(2):923-37. PubMed ID: 8627575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.